{"id":663,"date":"2002-01-01T12:00:00","date_gmt":"2002-01-01T11:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/renoprotektive-wirkungen-von-irbesartan-und-losartan"},"modified":"2022-03-17T14:10:03","modified_gmt":"2022-03-17T13:10:03","slug":"renoprotektive-wirkungen-von-irbesartan-und-losartan","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/renoprotektive-wirkungen-von-irbesartan-und-losartan","title":{"rendered":"Renoprotektive Wirkungen von Irbesartan und Losartan"},"content":{"rendered":"<p>Die IRMA-II-, IDNT- und RENAAL-Studie Zusammenfassung: In drei gro\u00dfen Studien haben sich die Angiotensin-II-Rezeptor-Blocker (AT-II-RB) Irbesartan bzw. Losartan als wirksam erwiesen, das Fortschreiten einer Nephropathie bei hypertensiven Typ-2-Diabetikern zu verz\u00f6gern. Dies betraf sowohl Fr\u00fchstadien (Mikroalbuminurie) wie auch fortgeschrittene Stadien (gro\u00dfe Proteinurie, eingeschr\u00e4nkte Nierenfunktion). Die Wirkung war st\u00e4rker als es dem Ausma\u00df der Blutdrucksenkung nach zu [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die IRMA-II-, IDNT- und RENAAL-Studie Zusammenfassung: In drei gro\u00dfen Studien haben sich die Angiotensin-II-Rezeptor-Blocker (AT-II-RB) Irbesartan bzw. Losartan als wirksam erwiesen, das Fortschreiten einer Nephropathie bei hypertensiven Typ-2-Diabetikern zu verz\u00f6gern. Dies betraf sowohl Fr\u00fchstadien (Mikroalbuminurie) wie auch fortgeschrittene Stadien (gro\u00dfe Proteinurie, eingeschr\u00e4nkte Nierenfunktion). Die Wirkung war st\u00e4rker als es dem Ausma\u00df der Blutdrucksenkung nach zu [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1611,316,309,312,314,313,315,317,320,311,307,319,310,324,155,1626,325,1627,1228,1628,134,321,1060,1625,1624,306],"class_list":["post-663","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-amlodipin","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-blutdruck","tag-diabetes-mellitus-typ-2","tag-diabetische-nephropathie","tag-hypertonie","tag-idnt-studie","tag-irbesartan","tag-irma-studie","tag-kalziumantagonisten","tag-losartan","tag-niereninsuffizienz","tag-renaal-studie","tag-renoprotektion","tag-sartane"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=663"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/663\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}